TY - JOUR
T1 - Neospora caninum
T2 - In vivo and in vitro treatment with artemisone
AU - Mazuz, Monica L.
AU - Haynes, Richard
AU - Shkap, Varda
AU - Fish, Leah
AU - Wollkomirsky, Ricardo
AU - Leibovich, Benjamin
AU - Molad, Thea
AU - Savitsky, Igor
AU - Golenser, Jacob
PY - 2012/6/8
Y1 - 2012/6/8
N2 - Neosporosis caused by Neospora caninum has global economic, clinical, and epidemiological impacts, mainly in the cattle industry. Currently, there is no useful drug for treatment of neosporosis. This publication is the first to describe the significant benefits that artemisone has on Neospora infections both in vitro and in vivo.Artemisone is a new semi-synthetic 10-alkylamino artemisinin that is superior to other artemisinin derivatives in terms of its significantly higher antimalarial activity, its tolerance in vivo, lack of detectable neurotoxic potential, improved in vivo pharmacokinetics and metabolic stability. Low micromolar concentrations of artemisone inhibited in vitro Neospora development. Prophylactic and post-infection treatment profoundly reduced the number of infected cells and parasites per cell. In the in vivo gerbil model, a non-toxic dose prevented typical cerebral symptoms, in most animals. There were no signs of clinical symptoms and brain PCR was negative. Most treated gerbils produced high specific antibody titer and were protected against a challenge. Overall, artemisone could be considered as a future drug for neosporosis.
AB - Neosporosis caused by Neospora caninum has global economic, clinical, and epidemiological impacts, mainly in the cattle industry. Currently, there is no useful drug for treatment of neosporosis. This publication is the first to describe the significant benefits that artemisone has on Neospora infections both in vitro and in vivo.Artemisone is a new semi-synthetic 10-alkylamino artemisinin that is superior to other artemisinin derivatives in terms of its significantly higher antimalarial activity, its tolerance in vivo, lack of detectable neurotoxic potential, improved in vivo pharmacokinetics and metabolic stability. Low micromolar concentrations of artemisone inhibited in vitro Neospora development. Prophylactic and post-infection treatment profoundly reduced the number of infected cells and parasites per cell. In the in vivo gerbil model, a non-toxic dose prevented typical cerebral symptoms, in most animals. There were no signs of clinical symptoms and brain PCR was negative. Most treated gerbils produced high specific antibody titer and were protected against a challenge. Overall, artemisone could be considered as a future drug for neosporosis.
KW - Artemisinin
KW - Artemisone
KW - Gerbil
KW - Neospora caninum
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=84860685371&partnerID=8YFLogxK
U2 - 10.1016/j.vetpar.2011.12.020
DO - 10.1016/j.vetpar.2011.12.020
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 22260899
AN - SCOPUS:84860685371
SN - 0304-4017
VL - 187
SP - 99
EP - 104
JO - Veterinary Parasitology
JF - Veterinary Parasitology
IS - 1-2
ER -